Financials data is unavailable for this security.
View more
Year on year Lincoln Pharmaceuticals Ltd had net income fall -11.74% from 933.05m to 823.46m despite a 7.35% increase in revenues from 5.81bn to 6.23bn. An increase in the selling, general and administrative costs as a percentage of sales from 32.55% to 34.84% was a component in the falling net income despite rising revenues.
| Gross margin | 53.64% |
|---|---|
| Net profit margin | 13.47% |
| Operating margin | 13.12% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2025, Lincoln Pharmaceuticals Ltd increased its cash reserves by 133.40%, or 76.67m. The company earned 930.16m from its operations for a Cash Flow Margin of 14.92%. In addition the company used 789.47m on investing activities and also paid 64.02m in financing cash flows.
| Cash flow per share | 50.87 |
|---|---|
| Price/Cash flow per share | 12.26 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -11.74%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.40% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 4.10% |
| EPS growth(5 years) | 9.84 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1.71 |
More ▼
